BiotechTube

BPS804

Phase 2Withdrawn
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Osteogenesis Imperfecta

Conditions

Osteogenesis Imperfecta

Trial Timeline

Oct 31, 2017 → Nov 1, 2018

NCT ID
NCT03216486

About BPS804

BPS804 is a phase 2 stage product being developed by Ultragenyx Pharmaceutical for Osteogenesis Imperfecta. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03216486. Target conditions include Osteogenesis Imperfecta.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT03216486Phase 2Withdrawn
NCT01417091Phase 2Completed

Competing Products

16 competing products in Osteogenesis Imperfecta

See all competitors
ProductCompanyStageHype Score
Teriparatide (FORTEO) + PlacebosEli LillyApproved
85
Zoledronic AcidNovartisPhase 2
52
Zoledronic AcidNovartisPhase 2
52
Zoledronic AcidNovartisPhase 3
77
Romosozumab + BisphosphonateAmgenPhase 3
76
RomosozumabAmgenPhase 1
32
DenosumabAmgenPhase 3
76
Denosumab + Alternative osteoporosis medicationsAmgenPhase 3
76
FresolimumabSanofiPhase 1
32
SAR439459 + PlaceboSanofiPhase 1
32
BPS804Ultragenyx PharmaceuticalPhase 2
47
SetrusumabUltragenyx PharmaceuticalPhase 2/3
60
SetrusumabUltragenyx PharmaceuticalPhase 2
47
setrusumabUltragenyx PharmaceuticalPhase 3
72
setrusumab + zoledronic acid (optional)Ultragenyx PharmaceuticalPhase 2
47
Bisphosphonate + SetrusumabUltragenyx PharmaceuticalPhase 3
72

Other Products from Ultragenyx Pharmaceutical

Crysvita (burosumab-twza) TreatmentApproved
80
GTX-102Phase 3
72
EvinacumabPhase 3
72
Adjuvant Immunomodulatory (IM) TherapyPhase 3
72
Oral prednisolone + Placebo for oral prednisolonePhase 3
72